Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial

BACKGROUND: Liver Transplantation (LT) is treatment of choice for patients with hepatocellular carcinoma (HCC) within MILAN Criteria. Tumour progression and subsequent dropout from waiting list have significant impact on the survival. Transarterial chemoembolization (TACE) controls tumour growth in...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Cancer
Main Authors: Hoffmann, Katrin, Ganten, Tom, Gotthardtp, Daniel, Radeleff, Boris, Settmacher, Utz, Kollmar, Otto, Nadalin, Silvio, Karapanagiotou-Schenkel, Irini, von Kalle, Christof, Jäger, Dirk, Büchler, Markus W, Schemmer, Peter
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2015
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4449604/
https://ncbi.nlm.nih.gov/pubmed/25957784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1373-z
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki